Skip to main content
Top
Published in: Reactions Weekly 1/2022

01-07-2022 | Myocardial Infarction | Case report

Bamlanivimab/casirivimab/imdevimab

Emetic episode or subacute antero-septal myocardial infarction with acute pulmonary oedema following off label use: case report

Published in: Reactions Weekly | Issue 1/2022

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Pellegrino G, et al. ANALYSIS OF THE USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF COVID-19 IN CLINICAL PRACTICE: A WEAPON IN THE FIGHT AGAINST THE PANDEMIC, ALONGSIDE VACCINATION. European Journal of Hospital Pharmacy - Science and Practice 29 (Suppl.): A200, Mar 2022. Available from: URL: http://doi.org/10.1136/ejhpharm-2022-eahp.418 [abstract] Pellegrino G, et al. ANALYSIS OF THE USE OF MONOCLONAL ANTIBODIES FOR THE TREATMENT OF COVID-19 IN CLINICAL PRACTICE: A WEAPON IN THE FIGHT AGAINST THE PANDEMIC, ALONGSIDE VACCINATION. European Journal of Hospital Pharmacy - Science and Practice 29 (Suppl.): A200, Mar 2022. Available from: URL: http://​doi.​org/​10.​1136/​ejhpharm-2022-eahp.​418 [abstract]
Metadata
Title
Bamlanivimab/casirivimab/imdevimab
Emetic episode or subacute antero-septal myocardial infarction with acute pulmonary oedema following off label use: case report
Publication date
01-07-2022
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-18704-1

Other articles of this Issue 1/2022

Reactions Weekly 1/2022 Go to the issue

Case report

Multiple drug

Case report

Multiple drugs

Case report

Remdesivir

Case report

Prednisolone